CombinatoRx Changes Company Name to Zalicus Inc.
New name reflects evolution as a pain and inflammation focused biopharmaceutical company
CombinatoRx, Incorporated announced that it has changed its name to Zalicus Inc. The company began trading under the new ticker symbol ZLCS on the NASDAQ Global Market at market open on September 9, 2010. The company also received a new CUSIP number (98887C 105) for its common stock. CombinatoRx merged with Neuromed Pharmaceuticals in December 2009 and has chosen a new name to highlight the assets, expertise and focus of the combined company.
“We have evolved into a new, multidimensional company following the completed integration of Neuromed and CombinatoRx and the commercial launch of Exalgo by Covidien. Under the Zalicus name we look forward to bringing innovative treatments to patients using the assets, expertise and focus of the merged company,” explained Mark H.N. Corrigan, MD, President and CEO of Zalicus. "Our new name reflects the Company’s transformation into a biopharmaceutical company with product revenues, two powerful and differentiated drug discovery platforms, a pipeline of product candidates and proven drug development expertise focused on the treatment of pain and inflammation.”
In conjunction with the name change, the company updated its development strategy for Synavive™, its most advanced clinical product candidate being developed for the treatment of immuno-inflammatory diseases. Zalicus is currently working to optimize and secure adequate supplies of its modified-release, once-daily capsule formulation of Synavive to meet anticipated clinical trial demands. This formulation is designed to provide greater efficacy through the optimal co-exposure of Synavive’s components, as well as an improved tolerability profile. In addition, based on feedback from leading practitioners in the arthritis field and compelling data from previous Synavive clinical trials, Zalicus plans to advance Synavive into further Phase 2 clinical development for the treatment of rheumatoid arthritis using its novel modified-release formulation, in early 2011.
Most read news
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Category:Posttranslational_modification
Genzyme to collaborate with Ablynx on MS research project
Dermoid_sinus
Scientists identify first genetic variant linked to biological aging in humans - Discovery has important implications for the understanding of cancer and age associated diseases
Oncolytics Biotech Inc. Successfully Completes Initial Scale Up of Manufacturing Process for REOLYSIN
